SDHB and adrenal gland pheochromocytoma: Our analysis suggests that enhanced GLUD1 expression is dependent on the downregulation of SDHB in PCC/PGL tumors, which thus may represent a potential biomarker and therapeutic target for SDHB-mutated tumors.